Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALGS
stocks logo

ALGS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
266.67K
-57.6%
-1.800
-86.26%
333.33K
+7.18%
-2.100
-141.02%
333.33K
-65.46%
-2.115
+38.24%
Estimates Revision
The market is revising Upward the revenue expectations for Aligos Therapeutics, Inc. (ALGS) for FY2025, with the revenue forecasts being adjusted by 11.34% over the past three months. During the same period, the stock price has changed by -11.02%.
Revenue Estimates for FY2025
Revise Upward
up Image
+11.34%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.6%
In Past 3 Month
Stock Price
Go Down
down Image
-11.02%
In Past 3 Month
Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.090
sliders
Low
50.00
Averages
50.00
High
50.00
Current: 10.090
sliders
Low
50.00
Averages
50.00
High
50.00
H.C. Wainwright
initiated
$50
2025-08-18
Reason
H.C. Wainwright
Price Target
$50
2025-08-18
initiated
Reason
H.C. Wainwright assumed coverage of Aligos Therapeutics with a Buy rating and $50 price target. The firm has conviction that ALG-000184 can become the new standard-of-care for chronic suppression of hepatitis B virus, while also serving as the oral backbone to future functional cure regimens.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$70
2025-03-31
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$70
2025-03-31
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Maintains
$75 → $70
2025-03-11
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$75 → $70
2025-03-11
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aligos Therapeutics Inc (ALGS.O) is -1.29, compared to its 5-year average forward P/E of -3.07. For a more detailed relative valuation and DCF analysis to assess Aligos Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.07
Current PE
-1.29
Overvalued PE
0.75
Undervalued PE
-6.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.80
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.76
Undervalued EV/EBITDA
-11.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
64.14
Current PS
0.00
Overvalued PS
224.51
Undervalued PS
-96.23
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 162.3% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALGS News & Events

Events Timeline

(ET)
2025-11-10
08:30:05
Aligos Therapeutics showcases findings from eight presentations at AASLD
select
2025-11-06 (ET)
2025-11-06
08:35:54
Aligos Therapeutics Announces Q3 EPS of $3.04, Exceeding Consensus Estimate of $2.01
select
2025-10-16 (ET)
2025-10-16
08:41:35
Aligos Therapeutics Secures USAN Council Approval for Pevifoscorvir Sodium
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
10-17Newsfilter
Aligos Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • Stock Options Granted: Aligos Therapeutics announced the grant of non-qualified stock options for 27,400 shares to newly hired employees as part of their 2024 Inducement Plan, effective October 15, 2025.

  • Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, contingent on continued employment.

[object Object]
Preview
8.5
09-17NASDAQ.COM
Biotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones

  • Prime Medicine Inc. Updates: Shares rose 8.14% after positive Q2 earnings, a narrowed net loss, and early clinical data from its CGD program. The company also completed a $144.2 million public offering and has upcoming IND filings for Wilson's Disease and AATD planned for 2026.

  • Elutia Inc. Developments: The stock increased by 10.17% following the announcement of clinical data showing significant improvements in reoperations for cardiac devices. Elutia will showcase its EluPro BioEnvelope at an upcoming technology exchange event.

  • Aligos Therapeutics Inc. Progress: Shares rose 2.79% after presenting preclinical studies at the International HBV Meeting, supporting its Phase 2 B-SUPREME trial. Upcoming catalysts include continued trial enrollment and a scheduled earnings report in November 2025.

  • Bionano Genomics Inc. Offering: The stock fell 35.74% due to a $10 million public offering announcement but rebounded 6.74% in after-hours trading. The funds will be used for working capital, and recent publications highlighted the utility of its Optical Genome Mapping technology.

[object Object]
Preview
4.0
09-12Benzinga
HC Wainwright & Co. Affirms Buy Rating for Aligos Therapeutics, Keeps $50 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aligos Therapeutics Inc (ALGS) stock price today?

The current price of ALGS is 10.09 USD — it has increased 2.23 % in the last trading day.

arrow icon

What is Aligos Therapeutics Inc (ALGS)'s business?

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

arrow icon

What is the price predicton of ALGS Stock?

Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aligos Therapeutics Inc (ALGS)'s revenue for the last quarter?

Aligos Therapeutics Inc revenue for the last quarter amounts to 741.00K USD, decreased -41.61 % YoY.

arrow icon

What is Aligos Therapeutics Inc (ALGS)'s earnings per share (EPS) for the last quarter?

Aligos Therapeutics Inc. EPS for the last quarter amounts to -3.04 USD, decreased -0.98 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aligos Therapeutics Inc (ALGS)'s fundamentals?

The market is revising Upward the revenue expectations for Aligos Therapeutics, Inc. (ALGS) for FY2025, with the revenue forecasts being adjusted by 11.34% over the past three months. During the same period, the stock price has changed by -11.02%.
arrow icon

How many employees does Aligos Therapeutics Inc (ALGS). have?

Aligos Therapeutics Inc (ALGS) has 70 emplpoyees as of December 05 2025.

arrow icon

What is Aligos Therapeutics Inc (ALGS) market cap?

Today ALGS has the market capitalization of 62.58M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free